Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study

2012 ◽  
Vol 18 (2) ◽  
pp. 212-218 ◽  
Author(s):  
Mats Sjöberg ◽  
Andrea Walch ◽  
Mina Meshkat ◽  
Anders Gustavsson ◽  
Gunnar Järnerot ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Observational Study ◽  
Rescue Therapy ◽  
Hospitalized Patients ◽  
Retrospective Observational Study ◽  
Steroid Refractory

scholarly journals Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational study

2012 ◽  
Vol 6 (6) ◽  
pp. 681-686 ◽  
Author(s):  
Filippo Mocciaro ◽  
Sara Renna ◽  
Ambrogio Orlando ◽  
Giulia Rizzuto ◽  
Emanuele Sinagra ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Observational Study ◽  
Rescue Therapy ◽  
Retrospective Observational Study ◽  
Term Data

scholarly journals Efficacy of Infliximab Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: Single Center Experience

2012 ◽  
Vol 10 (2) ◽  
pp. 152 ◽  
Author(s):  
Jun Hyung Cho ◽  
Chang Kyun Lee ◽  
Hyo Jong Kim ◽  
Jae Jun Shim ◽  
Jae Young Jang ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Rescue Therapy ◽  
Hospitalized Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Steroid Refractory

scholarly journals The Use of Infliximab for Treatment of Hospitalized Patients with Acute Severe Ulcerative Colitis

2008 ◽  
Vol 22 (11) ◽  
pp. 937-940 ◽  
Author(s):  
B Bressler ◽  
JK Law ◽  
N Al Nahdi Sheraisher ◽  
K Atkinson ◽  
MF Byrne ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Life Experience ◽  
Rescue Therapy ◽  
Real Life ◽  
Case Series ◽  
Hospitalized Patients ◽  
Severe Ulcerative Colitis ◽  
Duration Of Disease ◽  
Intravenous Steroids ◽  
Steroid Refractory

BACKGROUND/AIM: The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC.METHODS: Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy.RESULTS: Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76%) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62%), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab.CONCLUSIONS: In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62% maintained response either as a bridge to azathioprine or maintenance infliximab.

scholarly journals P237 Annual incidence and prevalence of ulcerative colitis and Crohn’s disease from 2010 to 2017 in four Nordic countries: Results from the TRINordic study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S261-S262
Author(s):  
M Lördal ◽  
J Burisch ◽  
E Langholz ◽  
T Knudsen ◽  
M Voutilainen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Observational Study ◽  
Nordic Countries ◽  
Annual Incidence ◽  
University Hospital ◽  
Retrospective Observational Study ◽  
Western World ◽  
The Impact

Abstract Background Incidence and prevalence of inflammatory bowel diseases (IBD) have been increasing for the past decades in the western world, however with an emerging trend of incidence stabilisation in recent years. There is an indication of higher IBD incidence and prevalence in northern Europe, especially in the Nordic region, compared with southern Europe. Methods This retrospective observational study collected data from the National Patient Registries and National Prescription Registries (Sweden [SWE], Norway [NOR], Denmark [DEN]) and one university hospital database (Turku, Finland [FIN]) during 2010–2017 to investigate the annual incidence and prevalence of ulcerative colitis (UC) and Crohn’s disease (CD). Patients with ≥2 ICD-10 diagnosis codes for UC (K51) or CD (K50) from 2010 or later and no K51 or K50 codes prior to 2010 were included; patients were classified according to their last code. The look-back period for SWE was until 2000, for NOR until 2008, for DEN until 1995, and for FIN until 2004. Incidence proportions highlight results through 2016, as 2017 patients had less than 1-year follow-up. Results In total, 69,876 patients were included (SWE n = 27,902, NOR n = 20,761, FIN n = 2,118, DEN n = 19,095), of which 44 367 patients were diagnosed with UC and 25,509 with CD. In 2016, the annual incidence of UC was 28 patients per 100,000 persons in NOR, 32 patients per 100,000 persons in DEN, 25 patients per 100,000 persons in SWE, and 44 patients per 100,000 in FIN. The corresponding results for the annual incidence of CD per 100,000 persons were 22 in NOR, 16 in DEN, 16 in SWE, and 21 in FIN. The prevalence per 100,000 persons of both UC and CD was the highest in DEN, followed by SWE and NOR, and lowest in FIN. Prevalence estimates increased in all four Nordic countries during 2010–2017: for UC, from 409 to 488 patients in SWE, from 256 to 428 in NOR, from 129 to 375 in FIN, and from 577 to 798 in DEN. For CD, it increased from 261 to 313 patients in SWE, from 164 to 258 in NOR, from 54 to 164 in FIN, and from 280 to 400 in DEN. Conclusion This retrospective observational study showed that during 2016, the annual incidence of UC ranged from 25–44 patients per 100,000 persons across the evaluated Nordic countries, whereas the annual incidence of CD was 16–22 patients per 100,000 persons. Prevalence of both UC and CD increased during 2010–2017 in all four countries. Estimates of UC and CD incidence and prevalence in this analysis are greater than reported in the published literature. Additional analyses are underway to further explore the impact of methodological decisions on the estimates of UC and CD annual incidence and prevalence.

W1116 Sequential Ciclosporine and Infliximab Rescue Therapy in Steroid Refractory Ulcerative Colitis

2009 ◽  
Vol 136 (5) ◽  
pp. A-657 ◽  
Author(s):  
Aoibhlinn M. O'Toole ◽  
Denise Keegan ◽  
Hugh Mulcahy ◽  
Diarmuid P. O'Donoghue
Keyword(s):  
Ulcerative Colitis ◽  
Rescue Therapy ◽  
Steroid Refractory
Sign in / Sign up

Export Citation Format

Share Document